Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS

Neurology. 2012 Nov 20;79(21):2160; author reply 2160. doi: 10.1212/01.wnl.0000423208.11698.16.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / chemically induced*
  • Leukoencephalopathy, Progressive Multifocal / chemically induced*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Substance Withdrawal Syndrome / diagnosis*

Substances

  • Antibodies, Monoclonal, Humanized